Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months ; volume:22 ; number:1 ; day:15 ; month:4 ; year:2022 ; pages:1-11 ; date:12.2022
BMC neurology ; 22, Heft 1 (15.4.2022), 1-11, 12.2022
- Urheber
-
Tichá, Veronika
Počíková, Zuzana
Vytlačil, Josef
Štěpánová, Radka
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-022-02656-8
- URN
-
urn:nbn:de:101:1-2022063018594488983770
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tichá, Veronika
- Počíková, Zuzana
- Vytlačil, Josef
- Štěpánová, Radka
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
Long‑term real‑world effectiveness and safety of fingolimod over 5 years in Germany
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Fingolimod Therapy for Multiple Sclerosis
Fingolimod for irradiation-induced neurodegeneration
Fingolimod (Addendum zum Auftrag A15-48)
Fingolimod: Nutzenbewertung gemäß § 35a SGB V
Multiple Sklerose – Beeinflusst Fingolimod die Immunantwort?
Fingolimod (Addendum zum Auftrag A14-21)
Fingolimod: Nutzenbewertung gemäß § 35a SGB V
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
Long‑term real‑world effectiveness and safety of fingolimod over 5 years in Germany
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Fingolimod Therapy for Multiple Sclerosis
Fingolimod for irradiation-induced neurodegeneration
Fingolimod (Addendum zum Auftrag A15-48)
Fingolimod: Nutzenbewertung gemäß § 35a SGB V
Multiple Sklerose – Beeinflusst Fingolimod die Immunantwort?
Fingolimod (Addendum zum Auftrag A14-21)
Fingolimod: Nutzenbewertung gemäß § 35a SGB V
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
Long‑term real‑world effectiveness and safety of fingolimod over 5 years in Germany
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
Fingolimod Therapy for Multiple Sclerosis
Fingolimod for irradiation-induced neurodegeneration
Fingolimod (Addendum zum Auftrag A15-48)
Fingolimod: Nutzenbewertung gemäß § 35a SGB V
Multiple Sklerose – Beeinflusst Fingolimod die Immunantwort?
Fingolimod (Addendum zum Auftrag A14-21)